Eli Lilly and Co (LLY)

81.59
NYSE : Health Care
Prev Close 80.40
Day Low/High 80.28 / 81.71
52 Wk Low/High 67.88 / 92.85
Avg Volume 4.19M
Exchange NYSE
Shares Outstanding 1.10B
Market Cap 88.75B
EPS 2.30
P/E Ratio 37.05
Div & Yield 2.04 (2.50%)

Latest News

Analyst: Merck's Fundamentals Don't Warrant Current Valuation

Analyst: Merck's Fundamentals Don't Warrant Current Valuation

BMO Capital Markets downgrades the pharmaceutical giant ahead of Q2 earnings as pricing pressure mounts and other potential headwinds begin to emerge.

Trump VP Pick Mike Pence's Indiana Record Shows Preference for Social Issues Over Business

Trump VP Pick Mike Pence's Indiana Record Shows Preference for Social Issues Over Business

Mike Pence could shore up Donald Trump's support among conservative Christians, but his record on business in Indiana is spotty at best.

3 Stocks Advancing The Health Care Sector

3 Stocks Advancing The Health Care Sector

TheStreet highlights 3 stocks pushing the health care sector higher today.

Lilly And Howard University Partner On Summer Medical Scientific Fellowship

Lilly And Howard University Partner On Summer Medical Scientific Fellowship

Unique program addresses industry's lack of underrepresented minorities

Insider Trading Alert - APOG, LLY And SNCR Traded By Insiders

Insider Trading Alert - APOG, LLY And SNCR Traded By Insiders

Stocks with insider trader activity include APOG, LLY and SNCR

Jim Cramer's 'Mad Money' Recap: What You Can Learn From My Portfolio Mistakes

Jim Cramer's 'Mad Money' Recap: What You Can Learn From My Portfolio Mistakes

Cramer has learned what works and what doesn't at Action Alerts PLUS. Here's how his thinking can help you profit.

6 High-Yield Dividend Stocks With Promising Charts  

6 High-Yield Dividend Stocks With Promising Charts  

The charts look favorable for these six high-yield dividend stocks. The stocks are among Deutsche Bank's list of best long ideas.

Medivation Shares Spike as Company Opens Door to Full-Fledged Auction

Medivation Shares Spike as Company Opens Door to Full-Fledged Auction

The company's shares were up nearly 2% in after hours trading.

Lilly Diabetes Welcomes Acclaimed Singer/Songwriter Crystal Bowersox As Newest Spokesperson

Lilly Diabetes Welcomes Acclaimed Singer/Songwriter Crystal Bowersox As Newest Spokesperson

Singer's moving story aims to help inspire children with type 1 diabetes to pursue their dreams

12 High-Yield Stocks From Deutsche Bank's Best Long Ideas

12 High-Yield Stocks From Deutsche Bank's Best Long Ideas

Following Brexit volatility, Deutsche Bank offered investors 42 best long ideas; here's the 12 stocks from the list with the highest dividend yields.

The Overbought Reading Will Be My Early July Focus

We are into resistance on the major indexes.

Nike Taps Apple CEO Tim Cook for Bigger Role

Nike Taps Apple CEO Tim Cook for Bigger Role

Nike's board of directors features a who's who of Fortune 500 executives.

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Eli Lilly Is on the Verge of a Powerful Breakout

Eli Lilly Is on the Verge of a Powerful Breakout

If Eli Lilly can blow through the $79 area, the stock has plenty of room to run on the upside.

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

FDA Advisory Committee Recommends Approval Of Jardiance® (empagliflozin) For Cardiovascular Indication In 12-11 Vote

FDA Advisory Committee Recommends Approval Of Jardiance® (empagliflozin) For Cardiovascular Indication In 12-11 Vote

Endocrinologic and Metabolic Drugs Advisory Committee votes in favor of CV mortality benefit for JARDIANCE for adults with type 2 diabetes

A Biotech Stock Turnaround Requires an Alzheimer's Drug Miracle

A Biotech Stock Turnaround Requires an Alzheimer's Drug Miracle

What if the only sentiment-turning catalyst left for biotech stocks this year is the outcome of Eli Lilly's Alzheimer's phase III study expected around Christmas?

Lilly Convenes Leaders At National Mayor's Conference To Address Impact Of Alzheimer's Disease On Local Communities

Lilly Convenes Leaders At National Mayor's Conference To Address Impact Of Alzheimer's Disease On Local Communities

Regional Community Conversations Events to Spark Creation of Preparedness Plans across the Nation

Eli Lilly And (LLY) Marked As A Barbarian At The Gate

Eli Lilly And (LLY) Marked As A Barbarian At The Gate

Trade-Ideas LLC identified Eli Lilly and (LLY) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Sanofi's Likely Sweetener for Medivation Panned

Sanofi's Likely Sweetener for Medivation Panned

The French drugmaker is reportedly thinking about including a CVR in its $9.3 billion bid for Medivation, but the move is unlikely to be enough to entice the target's shareholders.

Elanco Opens State-of-the-Art Vaccines Innovation Center

Elanco Opens State-of-the-Art Vaccines Innovation Center

Research to focus on unmet needs in animal health, including antibiotic alternatives

Elanco, EnBiotix Establish Collaboration Exploring Engineered Phage Technology

Elanco, EnBiotix Establish Collaboration Exploring Engineered Phage Technology

Today Elanco Animal Health, a division of Eli Lilly and Company, (NYSE: LLY) and EnBiotix, Inc.

Cramer: Here's What's Really Behind This Hatred for Biotechs

This is the group that is the most dangerous politically.

Jim Cramer's 'Mad Money' Recap: We've Seen This 'Brexit' Movie Before

Jim Cramer's 'Mad Money' Recap: We've Seen This 'Brexit' Movie Before

Sure, we're in a bad moment but is it really worth ditching high-quality stocks to run for the hills? Cramer asks.

German Supreme Court Grants Lilly Appeal In Alimta® Vitamin Regimen Patent Lawsuit

German Supreme Court Grants Lilly Appeal In Alimta® Vitamin Regimen Patent Lawsuit

Alimta Case Returned to Court of Appeal for New Ruling

Jardiance® (empagliflozin) Significantly Reduced The Risk Of Progressive Kidney Disease In Adults With Type 2 Diabetes With Established Cardiovascular Disease

Jardiance® (empagliflozin) Significantly Reduced The Risk Of Progressive Kidney Disease In Adults With Type 2 Diabetes With Established Cardiovascular Disease

-- JARDIANCE is the only SGLT2 inhibitor to demonstrate the potential to improve kidney outcomes on top of standard of care